20 Trailblazers Setting The Standard In ADHD Medication Pregnancy
20 Trailblazers Setting The Standard In ADHD Medication Pregnancy
Blog Article
ADHD Medication During Pregnancy and Breastfeeding
The decision to stop or keep ADHD medication during pregnancy and nursing is challenging for women with the condition. There aren't enough data on how long-term exposure may affect a fetus.
A recent study published in Molecular Psychiatry shows that children exposed to ADHD medication during utero do not develop neurological developmental disorders such as hearing or vision impairment seizures, febrile seizures or IQ impairment. The authors acknowledge that further high-quality studies are required.
Risk/Benefit Analysis
Women who are pregnant and take ADHD medication should evaluate the benefits of using it against the potential dangers for the foetus. Doctors don't have the necessary data to give clear guidelines, but they can provide information regarding benefits and risks that can assist pregnant women in making informed choices.
A study published in Molecular Psychiatry found that women who were taking ADHD medications during their early pregnancy did not have an increased risk of fetal cardiac malformations or major birth defects that are structural. Researchers used a vast population-based study of case-control to evaluate the incidence of major structural birth defects in infants born to mothers who had taken stimulants during the early stages of pregnancy, as well as those who had not. Pediatric cardiologists, clinical geneticists and other experts looked over the cases to ensure that the classification was correct and to minimize any bias.
However, the study had its limitations. Researchers were unable to, in the first place to distinguish the effects caused by the medication from the disorder. This makes it difficult for researchers to determine whether the small differences observed between the exposed groups were due to the use of medications or if they were affected by co-morbidities. The researchers did not study the long-term effects for the offspring.
The study did find that infants whose mothers took ADHD medication during pregnancy were at slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than infants whose mothers had not taken any medication or cut back on their medications prior to or during pregnancy. This increase was caused by central nervous system disorders. The higher risk of admission was not affected by the stimulant medications used during pregnancy.
Women who took stimulant ADHD medication during pregnancy also had an elevated risk of having a caesarean section or having a child with a low Apgar score (less than 7). These increases appeared to be unrelated to the type of medication used during pregnancy.
Researchers suggest that the minor risks associated with the use ADHD medication during pregnancies in the early stages could be offset by the more beneficial outcomes for both baby and mother of continued treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, when they are able, assist them in developing strategies to improve their coping abilities that can lessen the effects of her disorder on her daily life and relationships.
Medication Interactions
As more women than ever before are being diagnosed with ADHD and treated with medication, the question of whether to keep or end treatment during pregnancy is one that more and more physicians confront. These decisions are usually taken without clear and authoritative evidence. Instead, doctors have to weigh their own knowledge and experience, as well as the experiences of other physicians and the research on the topic.
In particular, the issue of possible risks to the infant can be difficult. The research on this subject is based on observation rather than controlled studies and a lot of the results are in conflict. The majority of studies restrict their analysis to live births, which can underestimate the severity of teratogenic effects leading to terminations or abortions of pregnancy. The study presented in this journal club addresses these shortcomings by analyzing data on live and deceased births.
Conclusion A few studies have found a positive correlation between ADHD medications and certain birth defects However, other studies haven't found a correlation. Most studies have shown that there is a neutral, or somewhat negative, impact. In each case an in-depth evaluation of the benefits and risks should be conducted.
For women suffering from ADHD, the decision to stop taking medication can be difficult, if not impossible. In fact, in an article published in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of isolation, and family conflict for these patients. Additionally, the loss of medication may affect the ability to perform jobs and drive safely that are crucial aspects of a normal life for many people suffering from ADHD.
She suggests that women who aren't sure whether to continue taking medication or stop due to pregnancy educate family members, colleagues, and acquaintances about the condition, its effects on daily functioning, and the benefits of continuing the current treatment plan. Educating them can also make the woman feel more comfortable when she is struggling with her decision. Certain medications can be passed through the placenta. If a patient decides to stop taking her ADHD medication while breastfeeding, it is important to be aware that the medication could be passed on to her baby.
Risk of Birth Defects
As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases, so do concerns about what impact the medications could have on foetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this subject. With two massive data sets researchers were able analyze more than 4.3 million pregnancies and determine whether the use of stimulant medications increased the risk of birth defects. Researchers discovered that although the overall risk is low, the first trimester ADHD medication exposure was associated with slightly higher risk of specific heart defects like ventriculoseptal defect.
The researchers behind the study found no association between early medication use and other congenital anomalies, such as facial clefting or club foot. The findings are in line with previous studies showing the presence of a small, but significant increase in the risk of heart malformations among women who began taking ADHD medications prior to pregnancy. The risk grew during the latter part of pregnancy, when a lot of women are forced to stop taking their medication.
Women who were taking ADHD medication in the first trimester were more likely to need a caesarean or have a low Apgar after delivery, and have a baby who needed help breathing when they were born. The authors of the study were unable to eliminate bias due to selection because they limited their study to women without other medical conditions that might have contributed to the findings.
The researchers hope their study will serve to inform the clinical decisions of physicians who treat pregnant women. The researchers recommend that, while discussing benefits and risks are important, the choice regarding whether or not to stop taking medication should be based on the severity of each woman's ADHD symptoms and her needs.
The authors also caution that while discontinuing the medications is an alternative, it is not a recommended practice because of the high rate of depression and other mental health problems in women who are pregnant or postpartum. Research has also shown that women who stop taking their medication will have a tough adjustment to life without them after the baby is born.
Nursing
It can be overwhelming to become a mother. Women with ADHD who have to manage their symptoms while attending doctor appointments and making preparations for the arrival of a child and adjusting to new household routines may face a lot of challenges. As such, many women choose to continue taking their ADHD medications throughout the course of pregnancy.
The majority of stimulant medicines are absorbed through breast milk in low quantities, so the risk to the infant who is breastfeeding is low. However, the frequency of medication exposure to the infant can differ based on dosage, frequency it is administered, and the time of the day it is administered. Additionally, different medications enter the baby's system differently through the gastrointestinal tract and breast milk, and the effect of this on a newborn infant is not yet fully understood.
Some physicians may discontinue stimulant medication during a woman's pregnancy due to the lack of research. It's a difficult choice for the mother, who must weigh the advantages of her medication against the potential risks to the foetus. Until more information is available, doctors should inquire with all pregnant patients about their history of ADHD and if they are planning or taking to take medication during the perinatal time.
A growing number of studies have proven that the majority of women are able to safely continue taking their ADHD medication during pregnancy and while breastfeeding. As a result, many patients opt click here to do this and in consultation with their doctor they have found that the benefits of keeping their current medication outweigh any potential risks.
It is crucial for women suffering from ADHD who are contemplating breastfeeding to seek out a specialist psychiatrist's advice prior to becoming pregnant. They should discuss the medication they are taking with their physician and discuss the pros and cons of continuing treatment. This includes non-pharmacological methods. Psychoeducation is also required to help women with ADHD be aware of their symptoms and the root cause, learn about available treatments and to reinforce existing coping strategies. This should be a multidisciplinary process including obstetricians, GPs and psychiatry. Pregnancy counseling should include a discussion of a treatment plan for the mother and the child, monitoring of indicators of deterioration, and, if needed modifications to the medication regime.